Articles from Galimedix Therapeutics, Inc.

Galimedix Therapeutics outlines development plans in Alzheimer's disease at CTAD 2026
Kensington, MD, USA and Munich/Martinsried, Germany, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Kensington, MD, USA and Munich/Martinsried, Germany, November 16, 2026 – Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, today announced that the Company is presenting new details on its planned Phase 2a development program to evaluate orally administered GAL-101 in patients with Alzheimer's disease at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference being held November 16-19, 2026 in Boston, MA.
By Galimedix Therapeutics, Inc. · Via GlobeNewswire · November 16, 2026
Galimedix Therapeutics presents baseline data from Phase 2 eDREAM trial highlighting patient-tailored microperimetry as a sensitive and precise functional measurement in geographic atrophy studies
Kensington, MD, USA, and Munich/Martinsried, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) --
By Galimedix Therapeutics, Inc. · Via GlobeNewswire · October 1, 2026
Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
Kensington, MD, USA and Munich/Martinsried, Germany, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Kensington, MD, USA, and Munich/Martinsried, Germany, September 11, 2026 – Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, today announced that functional feasibility data from its Phase 2 eDREAM study evaluating GAL-101 in geographic atrophy (GA), a severe form of dry age-related macular degeneration (AMD), will be presented at the upcoming 26th EURETINA Congress. The congress will take place October 1-4, 2026 in Vienna, Austria. The data will showcase the use of patient-tailored microperimetry as a sensitive functional endpoint for evaluating potential treatment effects in the eDREAM study.
By Galimedix Therapeutics, Inc. · Via GlobeNewswire · September 11, 2026
Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
Kensington, MD, USA and Munich/Martinsried, Germany, March 20, 2026 (GLOBE NEWSWIRE) --
By Galimedix Therapeutics, Inc. · Via GlobeNewswire · March 20, 2026
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
Kensington, MD, USA and Munich/Martinsried, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
By Galimedix Therapeutics, Inc. · Via GlobeNewswire · March 12, 2026
Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference
Kensington, MD, USA and Munich/Martinsried, Germany, March 05, 2026 (GLOBE NEWSWIRE) -- Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference
By Galimedix Therapeutics, Inc. · Via GlobeNewswire · March 5, 2026
Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Kensington, MD, USA and Munich/Martinsried, Germany, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
By Galimedix Therapeutics, Inc. · Via GlobeNewswire · December 4, 2025
Articles from Galimedix Therapeutics, Inc. | Hannibal Courier - Post